Antibe Therapeutics (TSE:ATE) Shares Up 13.5%

Antibe Therapeutics Inc. (TSE:ATEGet Free Report) shares rose 13.5% on Monday . The stock traded as high as C$0.35 and last traded at C$0.30. Approximately 167,042 shares changed hands during trading, an increase of 23% from the average daily volume of 135,475 shares. The stock had previously closed at C$0.26.

Antibe Therapeutics Trading Up 13.5 %

The company has a fifty day moving average of C$0.30 and a 200-day moving average of C$0.58. The company has a market capitalization of C$15.64 million, a price-to-earnings ratio of -0.84 and a beta of 0.19. The company has a current ratio of 10.06, a quick ratio of 9.58 and a debt-to-equity ratio of 0.29.

Antibe Therapeutics Company Profile

(Get Free Report)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).

Read More

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.